In vivo application of a small molecular weight antifungal protein of Penicillium chrysogenum (PAF)

Toxicology and Applied Pharmacology

Volumn 269, Issue 1, 2013, Pages 8-16

  Palicz, Zoltán ^a   Jenes, Ágnes ^a   Gáll, Tamás ^a   Miszti Blasius, Kornél ^a   Kollár, Sándor ^b   Kovács, Ilona ^b   Emri, Miklós ^a   Márián, Teréz ^a   Leiter, Éva ^c   Pócsi, István ^c   Csosz, Éva ^a   Kalló, Gergo ^a   Hegedus, Csaba ^a   Virág, László ^a   Csernoch, László ^a   Szentesi, Péter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Kenezy Hospital   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Antifungal protein; Aspergillosis; Histology; Mouse; PET

Indexed keywords

ANTIFUNGAL AGENT; ANTIFUNGAL PROTEIN OF PENICILLIUM CHRYSOGENUM; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FUNGUS GROWTH; GROWTH INHIBITION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INOCULATION; IRRITANT DERMATITIS; KIDNEY; LIVER; LUNG; LUNG ASPERGILLOSIS; LUNG EDEMA; MASS SPECTROMETRY; MOUSE; NONHUMAN; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; THICKNESS;

ADMINISTRATION, INHALATION; ANIMALS; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUNGAL PROTEINS; KIDNEY; LIVER; LUNG; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; PENICILLIUM CHRYSOGENUM; POSITRON-EMISSION TOMOGRAPHY; RISK ASSESSMENT; SKIN; TIME FACTORS; TOXICITY TESTS;

ANIMALIA; ARTHRODERMATACEAE; ASPERGILLUS; FUNGI; MAMMALIA; MUS; PENICILLIUM CHRYSOGENUM;

EID: 84875628562     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.02.014     Document Type: Article

References (34)

1. Bai P., Hegedus C., Szabó E., Gyüre L., Bakondi E., Brunyánszki A., Gergely S., Szabó C., Virág L. Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity. J. Investig. Dermatol. 2009, 129:234-238.
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
3. 18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 286:L834-L840.
4. Crawford F., Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst. Rev. 2007, 18:CD001434.
5. Denning D.W. Invasive aspergillosis. Clin. Infect. Dis. 1998, 26:781-803.
6. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., Haas A., Ruhnke M., Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. 2002, 34:563-571.
7. Galgoczy L., Papp T., Pocsi I., Hegedus N., Vagvolgyi C. In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes. Antonie Van Leeuwenhoek 2008, 94:463-470.
8. Hagan G., Southwood M., Treacy C., Ross R.M., Soon E., Coulson J. 18FDG PET imaging can quantify increased cellular metabolism in pulmonary arterial hypertension: A proof-of-principle study. Pulm. Circ. 2011, 1:448-455.
9. Hamacher K., Coenen H.H., Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 1986, 27(2):235-238.
10. 18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma. J. Nucl. Med. 2011, 52:1713-1720.
11. Hatori A., Yui J., Yamasaki T., Xie L., Kumata K., Fujinaga M., Yoshida Y., Ogawa M., Nengaki N., Kawamura K., Fukumura T., Zhang M.R. PET imaging of lung inflammation with [18F]FEDAC, a radioligand for translocator protein (18kDa). PLoS One 2012, 7(9):e45065.
12. Hegedus N., Leiter É., Kovács B., Tomori V., Kwon N.J., Emri T., Marx F., Batta G., Csernoch L., Haas H., Yu J.H., Pócsi I. The small molecular mass antifungal protein of Penicillium chrysogenum - a mechanism of action oriented review. J. Basic Microbiol. 2011, 51(6):561-571.
13. Howard S.J., Cerar D., Anderson M.J., Albarrag A., Fisher M.C., Pasqualotto A.C., Laverdiere M., Arendrup M.C., Perlin D.S., Denning D.W. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 2009, 15(7):1068-1076.
14. James A., Jorgensen C. Basic design of MRM Assay for peptide quantification. Methods Mol. Biol. 2010, 658:167-185.
15. Kaiserer L., Oberparleiter C., Weiler-Gorz R., Burgstaller W., Leiter E., Marx F. Characterization of the Penicillium chrysogenum antifungal protein PAF. Arch. Microbiol. 2003, 180:204-210.
16. Lajtos I., Emri M.S., Kis A., Opposits G., Pótári N., Kiraly B., Nagy F., Trón L., Balkay L. Performance evaluation and optimization of the MiniPET-II scanner. Nucl. Instr. Meth. Physics Res. Sect. A 2013, 707:26-34.
17. Leiter E., Szappanos H., Oberparleiter C., Kaiserer L., Csernoch L., Pusztahelyi T., Emri T., Pócsi I., Salvenmoser W., Marx F. Antifungal protein PAF severely affects the integrity of the plasma membrane of Aspergillus nidulans and induces an apoptosis-like phenotype. Antimicrob. Agents Chemother. 2005, 49(6):2445-2453.
18. Limper A.H., Knox K.S., Sarosi G.A., Ampel N.M., Bennett J.E., Catanzaro A., Davies S.F., Dismukes W.E., Hage C.A., Marr K.A., Mody C.H., Perfect J.R., Stevens D.A. An official American Thoracic Society Statement: treatment of fungal infections in adult pulmonary and critical care patients. Am. J. Respir. Crit. Care Med. 2011, 183:96-128.
19. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., Sable C.A., Kartsonis N.A., Ngai A., Taylor A., Patterson T.F., Denning D.W., Walsh T.J. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin. Infect. Dis. 2004, 39:1563-1571.
20. Marian T., Balkay L., Tron L., Krasznai Z.T., Szabo-Peli J., Krasznai Z. Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-d-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells. Eur. J. Pharm. Sci. 2005, 24:495-501.
21. Marr K.A., Patterson T., Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am. 2002, 16(4):875-894. (vi).
22. Marx F., Haas H., Reindl M., Stöffler G., Lottspeich F., Redl B. Cloning, structural organization and regulation of expression of the Penicillium chrysogenum paf gene encoding an abundantly secreted protein with antifungal activity. Gene 1995, 167:167-171.
23. Marx F., Binder U., Leiter E., Pócsi I. The Penicillium chrysogenum antifungal protein PAF, a promising tool for the development of new antifungal therapies and fungal cell biology studies. Cell Mol. Life Sci. 2008, 65:445-454.
24. Miszti-Blasius K., Debreceni I.B., Felszeghy S., Dezso B., Kappelmayer J. Lack of P-selectin glycoprotein ligand-1 protects mice from thrombosis after collagen/epinephrine challenge. Thromb. Res. 2011, 127(3):228-234.
25. Numata M., Suzuki S., Miyazawa N., Miyashita A., Nagashima Y., Inoue S., Kaneko T., Okubo T. Inhibition of inducible nitric oxide synthase prevents LPS-induced acute lung injury in dogs. J. Immunol. 1998, 160:3031-3037.
26. Oberparleiter C., Kaiserer L., Haas H., Ladurner P., Andratsch M., Marx F. Active internalization of the Penicillium chrysogenum antifungal protein PAF in sensitive aspergilli. Antimicrob. Agents Chemother. 2003, 47:3598-3601.
27. Palicz Z., Füzi M., Szentesi P., Hegedus C., Leiter E., Pocsi I., Csernoch L. In vivo test of a highly stable antifungal protein (PAF) against lung aspergillosis. Acta Physiol. Hung. 2010, 97:468.
28. Patterson T.F., Kirkpatrick W.R., White M., Hiemenz J.W., Wingard J.R., Dupont B., Rinaldi M.G., Stevens D.A., Graybill J.R. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000, 79:250-260.
29. Puljic R., Benediktus E., Plater-Zyberk C., Baeuerle P.A., Szelenyi S., Brune K., Pahl A. Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur. J. Pharmacol. 2007, 557:230-235.
30. Shibuya K., Ando T., Hasegawa C., Wakayama M., Hamatani S., Hatori T., Nagayama T., Nonaka H. Pathophysiology of pulmonary aspergillosis. J. Infect. Chemother. 2004, 10(3):138-145.
31. Smith N.L., Denning D.W. Underlying conditions in chronic pulmonary aspergillosis, including simple aspergilloma. Eur. Respir. J. 2011, 37:865-872.
32. Szabo E., Virag L., Bakondi E., Gyure L., Hasko G., Bai P., Hunyadi J., Gergely P., Szabo C. Peroxynitrite production, DNA breakage, and poly(ADPribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity. J. Investig. Dermatol. 2001, 117:74-80.
33. Szappanos H., Szigeti G.P., Pál B., Rusznák Z., Szucs G., Rajnavölgyi É., Balla J., Balla G., Nagy E., Leiter É., Pócsi I., Marx F., Csernoch L. The Penicillium chrysogenum-derived antifungal peptide shows no toxic effects on mammalian cells in the intended therapeutic concentration. Naunyn Schmiedebergs Arch. Pharmacol. 2005, 371:122-132.
34. Vandeputte P., Ferrari S., Coste A.T. Antifungal resistance and new strategies to control fungal infections. Int. J. Microbiol. 2012, (Article ID 713687).